PayPoint plc : Holding(s) in Company TR-1: Standard form

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
12
PayPoint plc : Holding(s) in Company

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: PayPoint Plc
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)
Non-UK issuer  
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments  
An event changing the breakdown of voting rights  
Other (please specify)iii:  
3. Details of person subject to the notification obligationiv
Name FIL Limited
City and country of registered office (if applicable) Pembroke, Bermuda
4. Full name of shareholder(s) (if different from 3.)v See Section 9
Name  
City and country of registered office (if applicable)  
5. Date on which the threshold was crossed or reachedvi: 04 January 2019
6. Date on which issuer notified (DD/MM/YYYY): 07 January 2019
7. Total positions of person(s) subject to the notification obligation
  % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached Below 5% Below 5% Below 5% 68,234,724
Position of previous notification (if
applicable)
5.85% 0.00% 5.85%  



8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix % of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00B02QND93   Below 5%   Below 5%
         
         
SUBTOTAL 8. A Below 5% Below 5%
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
         
         
         
    SUBTOTAL 8. B 1    
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
           
           
           
      SUBTOTAL 8.B.2    
 


9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii  
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
FIL Limited      
FIL Holdings (UK) Limited      
FIL Investments International      
       
FIL Limited      
FIL Fund Management (Ireland) Limited      
       
FIL Limited      
FIL Limited      
 
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
The number and % of voting rights held N/A
The date until which the voting rights will be held N/A
 
11. Additional informationxvi
 

N/A


Place of completion Dublin
Date of completion 07 January 2019

Enquiries for PayPoint Plc:

Susan Court, Company Secretary
+44 (0) 1707 600 300

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading